Flexion Therapeutics, Inc. (FLXN): Price and Financial Metrics


Flexion Therapeutics, Inc. (FLXN): $6.62

0.25 (+3.92%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

FLXN POWR Grades


  • Growth is the dimension where FLXN ranks best; there it ranks ahead of 85.82% of US stocks.
  • The strongest trend for FLXN is in Momentum, which has been heading down over the past 48 weeks.
  • FLXN ranks lowest in Stability; there it ranks in the 7th percentile.

FLXN Stock Summary

  • Flexion Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 3.18% of US listed stocks.
  • FLXN's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of just 1.96% of US stocks.
  • The volatility of Flexion Therapeutics Inc's share price is greater than that of 87.46% US stocks with at least 200 days of trading history.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Flexion Therapeutics Inc are JAGX, GKOS, BNFT, TUFN, and AZPN.
  • FLXN's SEC filings can be seen here. And to visit Flexion Therapeutics Inc's official web site, go to www.flexiontherapeutics.com.

FLXN Valuation Summary

  • In comparison to the median Healthcare stock, FLXN's EV/EBIT ratio is 119.45% lower, now standing at -5.7.
  • FLXN's EV/EBIT ratio has moved up 6 over the prior 92 months.
  • Over the past 92 months, FLXN's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for FLXN.

Stock Date P/S P/B P/E EV/EBIT
FLXN 2021-08-31 2.9 -5.4 -3.2 -5.7
FLXN 2021-08-30 2.8 -5.2 -3.1 -5.6
FLXN 2021-08-27 2.9 -5.4 -3.2 -5.7
FLXN 2021-08-26 2.7 -5.0 -2.9 -5.4
FLXN 2021-08-25 3.0 -5.4 -3.2 -5.8
FLXN 2021-08-24 2.6 -4.8 -2.8 -5.2

FLXN Growth Metrics

  • Its year over year net income to common stockholders growth rate is now at 27.29%.
  • Its 5 year net income to common stockholders growth rate is now at -257.66%.
  • Its 3 year price growth rate is now at 12.69%.
FLXN's revenue has moved up $20,218,000 over the prior 15 months.

The table below shows FLXN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 102.738 -59.19 -95.049
2021-03-31 90.014 -60.838 -105.46
2020-12-31 85.552 -70.561 -113.706
2020-09-30 82.896 -99.761 -127.575
2020-06-30 81.018 -119.002 -141.169
2020-03-31 82.52 -138.974 -145.037

FLXN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • FLXN has a Quality Grade of C, ranking ahead of 50.07% of graded US stocks.
  • FLXN's asset turnover comes in at 0.43 -- ranking 108th of 677 Pharmaceutical Products stocks.
  • HSKA, AZN, and SPPI are the stocks whose asset turnover ratios are most correlated with FLXN.

The table below shows FLXN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.430 0.780 -0.241
2021-03-31 0.354 0.744 -0.278
2020-12-31 0.345 0.775 -0.313
2020-09-30 0.346 0.797 -0.367
2020-06-30 0.345 0.820 -0.414
2020-03-31 0.367 0.873 -0.415

FLXN Price Target

For more insight on analysts targets of FLXN, see our FLXN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $18.00 Average Broker Recommendation 1.41 (Moderate Buy)

FLXN Stock Price Chart Interactive Chart >

Price chart for FLXN

FLXN Price/Volume Stats

Current price $6.62 52-week high $13.66
Prev. close $6.37 52-week low $4.30
Day low $6.32 Volume 960,910
Day high $6.66 Avg. volume 891,519
50-day MA $5.97 Dividend yield N/A
200-day MA $8.99 Market Cap 332.93M

Flexion Therapeutics, Inc. (FLXN) Company Bio


Flexion Therapeutics focuses on the development and commercialization of anti-inflammatory and analgesic therapies for the treatment of patients with musculoskeletal conditions. The company was founded in 2007 and is based in Burlington, Massachusetts.


FLXN Latest News Stream


Event/Time News Detail
Loading, please wait...

FLXN Latest Social Stream


Loading social stream, please wait...

View Full FLXN Social Stream

Latest FLXN News From Around the Web

Below are the latest news stories about Flexion Therapeutics Inc that investors may wish to consider to help them evaluate FLXN as an investment opportunity.

Flexion Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

BURLINGTON, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a virtual analyst-led fireside chat at the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021.

Intrado Digital Media | September 8, 2021

Flexion Therapeutics to Present at the Wells Fargo 2021 Virtual Healthcare Conference

BURLINGTON, Mass., Sept. 03, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (NASDAQ: FLXN ) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the Wells Fargo 2021 Virtual Healthcare Conference. The virtual fireside chat Full story available on Benzinga.com

Benzinga | September 3, 2021

Flexion Therapeutics Announces Inclusion of ZILRETTA® in American Academy of Orthopaedic Surgeons (AAOS) Clinical Practice Guidelines for the Management of Osteoarthritis of the Knee

BURLINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced that the American Academy of Orthopaedic Surgeons (AAOS) included ZILRETTA (triamcinolone acetonide extended-release injectable suspension) in its updated evidence-based clinical practice guidelines for the management of osteoarthritis (OA) of the knee. 1

Intrado Digital Media | September 2, 2021

Flexion Therapeutics (FLXN) Upgraded to Buy: Here's What You Should Know

Flexion Therapeutics (FLXN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Yahoo | August 30, 2021

Why Is Flexion Therapeutics (FLXN) Stock Gaining On Wednesday?

Flexion Therapeutics Inc (NASDAQ: FLXN) expanded the Phase 1b trial of FX301 in patients undergoing bunionectomy. Related: Flexion Therapeutics To Start Testing FX301 For Post-Op Pain In Patients After Musculoskeletal Surgery. FX301 is a formulation of a locally administered NaV1.7 inhibitor (funapide) which aims to provide at least three to five days of post-operative pain relief while preserving motor function. The Company's decision to advance FX301 into the expansion cohort following a revie

Yahoo | August 25, 2021

Read More 'FLXN' Stories Here

FLXN Price Returns

1-mo 24.44%
3-mo -28.20%
6-mo -26.85%
1-year -37.07%
3-year -63.63%
5-year -63.26%
YTD -42.63%
2020 -44.25%
2019 82.86%
2018 -54.79%
2017 31.65%
2016 -1.30%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.0147 seconds.